Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay, Pierre Levy

To cite this version:
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, et al.. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS ONE, 2020, 15 (1), pp.e0225301. 10.1371/journal.pone.0225301. hal-03655987

HAL Id: hal-03655987
https://hal.science/hal-03655987
Submitted on 3 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
RESEARCH ARTICLE

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

Kevin Bowrin1*, Jean-Baptiste Briere2*, Laurent Fauchier3*, Craig Coleman4*, Aurélie Millier5*, Mondher Toumi6*, Emilie Clay5*, Pierre Levy7*

1 Bayer Plc, Reading, England, United Kingdom, 2 Bayer AG, Berlin, Germany, 3 Cardiologie, Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France, 4 University of Connecticut, School of Pharmacy, Storrs, Connecticut, United States of America, 5 Creativ-CEPTAL, Paris, France, 6 Aix-Marseille University, Marseille, France, 7 Université Paris-Dauphine, PSL Research University, LEDA-LEGO S, Paris, France

☯ These authors contributed equally to this work.
* kevin.bowrin@bayer.com

Abstract

Objective

The objective was to assess the real-world cost-effectiveness of rivaroxaban, versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation (AF) from a French national health insurance perspective.

Methods

A Markov model was developed with a lifetime horizon and cycle length of 3 months. All inputs were drawn from real-world evidence (RWE) studies: data on baseline patient characteristics at model entry were obtained from a French RWE study, clinical event rates as well as persistence rates for the VKA treatment arm were estimated from a variety of RWE studies, and a meta-analysis provided comparative effectiveness for rivaroxaban compared to VKA. Model outcomes included costs (drug costs, clinical event costs, and VKA monitoring costs), quality-adjusted life-years (QALY) and life-years (LY) gained, incremental cost per QALY, and incremental cost per LY. Sensitivity analyses were performed to test the robustness of the model and to better understand the results drivers.

Results

In the base-case analysis, the incremental total cost was €714 and the total incremental QALYs and LYs were 0.12 and 0.16, respectively. The resulting incremental cost/QALY and incremental cost/LY were €6,006 and €4,586, respectively. The results were more sensitive to the inclusion of treatment-specific utility decrements and clinical event rates.
Conclusions

Although there is no official willingness-to-pay threshold in France, these results suggest that rivaroxaban is likely to be cost-effective compared to VKA in French patients with AF from a national insurance perspective.

Introduction/Background

Atrial fibrillation (AF) is a cardiac arrhythmia with structural and/or electrophysiological abnormalities that induce remodelling in the atria; it is the most common cardiac arrhythmia [1–3]. Worldwide, an estimated 3% of adults aged 20 years or older suffer from AF, approximately 20.9 million men and 12.6 million women [2]. Due to the aging of the population, the worldwide prevalence is predicted to at least double in many countries during the next several decades [4, 5].

AF is associated with substantial morbidity and mortality [2]. Compared to otherwise healthy individuals, men and women with AF are at a 1.5-fold and 2-fold increased risk for all-cause mortality, respectively [2], and the risk for strokes increased by 2-to-7-fold [4]. Strokes are associated with significant financial burden [6]; in 2015, the total costs of stroke care in the European Union (EU) was estimated to be €45 billion euros [7]. It is expected that between 2015 and 2035, there will be a 34% increase in total number of stroke events in the European Union [7].

Oral anticoagulants including vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban, have been established as a cornerstone of management in patients with AF and to reduce stroke incidence and mortality [2] in randomized clinical trials (RCTs) [2].

Many uncertainties remain regarding the relevance of the results of RCTs in a real-world setting. Real-world evidence (RWE) may provide additional information to decision-makers [8]. Indeed, RWE sample size is not limited as it is the case of RCTs. RCTs have to respect inclusion/exclusion criteria regarding population selection. Also, RWE can offer long-term outcomes while the timeframe of RCT is usually shorter with only a few outcomes [9].

A meta-analysis comparing NOACs with VKAs and reporting effectiveness, safety, and persistence using RWE has recently been published [10]. It confirmed the findings of rivaroxaban pivotal RCT [11] and concluded that rivaroxaban is a suitable alternative to VKAs in routine clinical practice. Health Technology Assessment (HTA) agencies are frequently requesting manufacturers to prove the benefits of their health technology in the real-world, not only in terms of clinical RWE but also in terms of RWE cost-effectiveness. Indeed, RWE is of interest since it reflects more closely what happens in a real-world setting. While many initial coverage and reimbursement decisions are based on cost-effectiveness models using RCT efficacy and safety data, the use of RWE can provide more realistic estimates of cost-effectiveness based on how the drug is being used in clinical practice, its effectiveness, safety, and associated costs. The availability of a RWE meta-analysis provides a good opportunity to evaluate the RWE cost-effectiveness of rivaroxaban compared to VKAs for the prevention of stroke in patients with AF.

In France, NOACs are acknowledged as an important component of the national stroke plan, but there is an increasing scrutiny regarding the cost of these therapies; therefore, a French national healthcare insurance (NHI) perspective was considered relevant to demonstrate the real-world value of these therapies.
Methods

Model approach

An already published Markov cost-effectiveness model [12] was adapted to assess the incremental costs and health outcomes of rivaroxaban compared to VKA in patients with AF in real-world settings (Fig 1). Patients enter the model initiating a first-line treatment with either rivaroxaban or VKA, and could progress between health states according to transition probabilities. Health states included stable AF, acute and post major ischaemic stroke (IS), acute and post minor IS, acute and post myocardial infarction (MI), acute and post intracranial haemorrhage (ICH), gastrointestinal (GI) bleed, and death. Patients were always at a risk of an event; however, the model assumed that only one event could occur per cycle. Additionally, long term consequences of an event were considered until death or until the occurrence of a subsequent event with long-term consequences. All patients could either be on-treatment (rivaroxaban, initial VKA or other VKA after a switch) or off-treatment (once all treatments are discontinued). Indeed, the model allowed all patients to discontinue their initial treatment, to switch (from rivaroxaban to VKA, from VKA to other VKA), or to stop treatment (from rivaroxaban or VKA to no treatment). Patients who had switched or discontinued treatment could still experience any clinical event.

The model outcomes included the number of IS, the number of MI, and the number of bleeds, as well as the total quality-adjusted life-years (QALY), the total life-years (LY) gained, the total costs and the incremental cost per QALY or per LY gained. All model inputs as presented in Table 1 were drawn from RWE studies.

Cycle length and time horizon

The model considered a lifetime time horizon (30 years) in order to fully capture the expected long-term costs and health effect consequences of AF in accordance with French guidelines.

---

Fig 1. Model diagram. Abbreviations: AF, atrial fibrillation; GI, gastrointestinal; ICH, intracranial haemorrhage; IS, ischaemic stroke; MI, myocardial infarction.

https://doi.org/10.1371/journal.pone.0225301.g001
Table 1. Model inputs: Three-month probabilities of events and discontinuation, mortality, utility and costs.

| Event | Value | Range used in DSA | Distribution used in PSA | Source |
|-------|-------|-------------------|--------------------------|--------|
| **Three-month probabilities (VKA arm)** |       |                   |                          |        |
| Minor IS | 0.151% | [0.146%; 0.155%] | Beta (4,539; 3,005,582) | Weighted average of event rates identified in Coleman et al. 2019 [10] + Hylek et al. 2003 [13] |
| Major IS | 0.217% | [0.211%; 0.223%] | Beta (4,536; 2,085,855) |        |
| MI | 0.193% | [0.181%; 0.205%] | Beta (1,037; 536,223) |        |
| GI bleed | 0.406% | [0.395%; 0.417%] | Beta (5,469; 1,341,752) |        |
| ICH | 0.199% | [0.190%; 0.208%] | Beta (1,778; 891,500) |        |
| **Discontinuation** |       |                   |                          |        |
| 0–3 months | 29.10% | [28.63%; 29.57%] | Beta (10,283; 25,053) | Coleman et al. 2016 [14] |
| 3–6 months | 17.07% | [16.67%; 17.46%] | Beta (6,031; 29,305) |        |
| 6–12 months | 15.48% | [15.11%; 15.86%] | Beta (5,472; 29,864) |        |
| 12+ months | 10.88% | [10.55%; 11.20%] | Beta (3,843; 31,493) |        |
| **Proportion of switch among discontinued patients** | 16.10% | [13.06%; 19.14%] | Beta (90; 469) | Collings et al. 2018 [15] |
| **Three-month probabilities (rivaroxaban arm)** |       |                   |                          |        |
| Minor IS | 0.125% | [0.113%; 0.140%] | Beta (343; 267,304) | HRs from Coleman et al. 2019 [10] applied to three-month probabilities of V KA arm |
| Major IS | 0.180% | [0.163%; 0.202%] | Beta (343; 185,544) |        |
| MI | 0.185% | [0.154%; 0.220%] | Beta (135; 73,678) |        |
| GI bleed | 0.495% | [0.455%; 0.540%] | Beta (472; 94,947) |        |
| ICH | 0.137% | [0.104%; 0.179%] | Beta (69; 51,161) |        |
| **Discontinuation** |       |                   |                          |        |
| 0–3 months | 18.04% | [17.46%; 18.92%] | Beta (1462; 6,268) |        |
| 3–6 months | 10.58% | [10.24%; 11.09%] | Beta (1603; 12,849) |        |
| 6–12 months | 9.60% | [9.29%; 10.06%] | Beta (1622; 14,492) |        |
| 12+ months | 6.74% | [6.53%; 7.07%] | Beta (1676; 22,032) |        |
| **Proportion of switch among discontinued patients** | 12.00% | [7.64%; 16.36%] | Beta (25; 187) | Collings et al. 2018 [15] |
| **Three-month probabilities (no treatment arm)** |       |                   |                          |        |

(Continued)
### Table 1. (Continued)

| Event                  | Value (HR)          | Range used in DSA (HR) | Distribution used in PSA | Source                                                                 |
|------------------------|---------------------|------------------------|--------------------------|------------------------------------------------------------------------|
| Minor IS               | 0.43% (HR: 2.91)    | [0.274%; 0.698%] (HR: [1.82; 4.66]) | Beta (27; 6,247)         | Unpublished HRs applied to three-month probabilities of VKA arm        |
| Major IS               | 0.629% (HR: 2.91)   | [0.394%; 1.005%] (HR: [1.82; 4.66]) | Beta (27; 4,324)         |                                                                        |
| MI                     | 0.453% (HR: 2.35)   | [0.147%; 1.610%] (HR: [0.76; 8.40]) | Beta (8; 1,837)          |                                                                        |
| GI bleed               | 0.094% (HR: 0.23)   | [0.024%; 0.296%] (HR: [0.06; 0.73]) | Beta (7; 7,507)          |                                                                        |
| ICH                    | 0.036% (HR: 0.18)   | [0.006%; 0.156%] (HR: [0.03; 0.77]) | Beta (6; 15,416)         |                                                                        |

**In-hospitalisation mortality rates per clinical event in model**

| Event                  | Value (HR)          | Range used in DSA (HR) | Distribution used in PSA | Source                                                                 |
|------------------------|---------------------|------------------------|--------------------------|------------------------------------------------------------------------|
| Minor IS               | 0.00% -             |                        | -                        | Assumption                                                             |
| Post minor IS          | 0.00% -             |                        | -                        | Assumption                                                             |
| Major IS               | 13.13% [12.66%; 13.60%] | Beta (2,614; 17,294)    | Fauchier et al. 2015 [16] |                                                                        |
| Post major IS          | 8.12% [7.35%; 8.92%] | Beta (390; 4,410)       | Lip et al. 2015 [17]     |                                                                        |
| MI                     | 8.28% [7.05%; 9.51%] | Beta (159; 1,760)       | Blin et al. 2016 [18]    |                                                                        |
| Post-MI                | 8.24% [7.17%; 9.34%] | Beta (211; 2,347)       | Lip et al. 2015 [17]     |                                                                        |
| ICH                    | 18.77% [16.96%; 20.58%] | Beta (335; 1,449)      | Fauchier et al. 2015 [16] |                                                                        |
| Post-ICH               | 14.11% [11.85%; 16.57%] | Beta (128; 781)        | Lip et al. 2015 [17]     |                                                                        |
| GI bleed               | 5.38% [3.90%; 6.85%] | Beta (48; 844)          | Cotte et al. 2014 [19]   |                                                                        |

**Utility values**

| Event                  | Value (HR)          | Range used in DSA (HR) | Distribution used in PSA | Source                                                                 |
|------------------------|---------------------|------------------------|--------------------------|------------------------------------------------------------------------|
| Stable                 | 0.73 [0.71; 0.75]   | Beta (1598; 600)       | Kongnakorn 2015 et al. [20] |                                                                        |
| Minor IS               | 0.73 [0.56; 0.68]   | Beta (163; 100)        | Luengo-Fernandez et al. 2013 [21] |                                                                        |
| Major IS               | 0.41 [0.48; 0.60]   | Beta (149; 127)        |                                                                        |                                                                        |
| Post minor IS          | 0.73 [0.45; 0.74]   | Beta (24; 17)          |                                                                        |                                                                        |
| Post major IS          | 0.56 [0.20; 0.34]   | Beta (45;121)          |                                                                        |                                                                        |
| MI                     | 0.66 [0.55; 0.67]   | Beta (162; 103)        | Pickett et al. 2014 [22]  |                                                                        |
| Post-MI                | 0.73 [0.46; 0.77]   | Beta (23; 15)          |                                                                        |                                                                        |
| ICH                    | 0.56 [0.61; 0.69]   | Beta (367; 196)        | Luengo-Fernandez et al. 2013 [21] |                                                                        |
| Post-ICH               | 0.67 [0.47; 0.51]   | Beta (999; 1044)       |                                                                        |                                                                        |
| GI bleed               | 0.70 [0.69; 0.72]   | Beta (3287;1395)       | Kongnakorn 2015 et al. [20] |                                                                        |

**Costs (€)**

| Event                  | Value (HR)          | Range used in DSA (HR) | Distribution used in PSA | Source                                                                 |
|------------------------|---------------------|------------------------|--------------------------|------------------------------------------------------------------------|
| Drug costs             |                     |                        |                          |                                                                        |
| Acquisition VKA (daily)| 0.13 -              | -                      | AMELI [23]               |                                                                        |
| Acquisition rivaroxaban (daily) | 2.02 -              | -                      | AMELI [24]               |                                                                        |
| Monitoring VKA (cycle) | 80.86 [64.27; 107.12] | Gamma (55; 1.4)       | Data on file             |                                                                        |
| Monitoring rivaroxaban (cycle) | 15.57 [11.67; 19.46] | Gamma (61; 0.3)       | Data on file             |                                                                        |
| IS                     |                     |                        |                          |                                                                        |
| Acute treatment (minor)| 3,975 [2,783; 5,158] | Gamma (43; 93)        | Lanitis et al. 2014 [25], based on Cotte et al. 2014 [19] |                                                                        |
| Acute treatment (major)| 12,574 [8,802; 16,346] | Gamma (43; 295)      |                                                                        |                                                                        |
| Monthly follow-up (minor) | 595 [417; 774]    | Gamma (43; 14)        |                                                                        |                                                                        |
| Monthly follow-up (major) | 2,382 [1,667; 3,096] | Gamma (43; 56)       |                                                                        |                                                                        |
| Rehabilitation         | 10,112 [7,584; 12,640] | Gamma (61; 165)      | Cotte et al. 2016 [26] (using stroke/TIA/SE as a proxy) |                                                                        |

(Continued)
The model cycle length was set to 3 months which was assumed sufficient to enable the capture of short-term events and their acute impact on costs and clinical outcomes.

**Study perspective**

This analysis was conducted from the French NHI perspective. The model was discounted at a rate of 4% for costs and benefits as recommended by pharmacoeconomic guidelines in France [27].

**Patients’ characteristics**

In order to ensure generalisability to the French AF population, the model was populated with clinical characteristics drawn from RWE studies, representative of the French AF population for which NOACs are indicated [28]. Patients entered the model at a mean age of 70 years, 15% had an intermediate CHA\(_2\)DS\(_2\)-VASc score (=1) and 85% had a high CHA\(_2\)DS\(_2\)-VASc score (≥2).

**Clinical data implementation**

RWE was used to inform clinical event rates for VKA, while rates for rivaroxaban were estimated by applying relevant RWE hazard ratios (HRs) to the VKA transition probabilities retrieved from the RWE meta-analysis on prevalent and incident patients [10]. Clinical event rates for patients using “other VKA” were assumed to be the same as for the initial VKA.

All studies included in the RWE meta-analysis provided annual rates for the VKA arm of the model. All retrieved annual rates were pooled using weighted means by sample size as weights, and were then converted to 3-month probabilities before the implementation in the model. As the model distinguishes between major and minor IS, it was necessary to consider the proportions of 59% of IS as major and 41% as minor [13]. Additionally, VKA risk for IS was adjusted by age according to the risk score calculator derived from the Framingham Heart Study [29]. The relative risk of IS for patients aged 70–74 years was set at 1.0; IS risk for all other age groups was calculated in relation to this subgroup (Table 2). Finally, the stroke risk

| Value     | Range used in DSA | Distribution used in PSA | Source                                      |
|-----------|------------------|--------------------------|---------------------------------------------|
| Acute Treatment (one event per cycle) | 4,289 [3,002; 5,576] | Gamma (43; 100)          | Lanitis et al. 2014 [25], based on Cotte et al. 2014 [19] |
| Monthly Follow-up | 1,045 [732; 1,359] | Gamma (43; 25)           |                                             |

Abbreviation: AMELI, official French Health Insurance website; DSA, deterministic sensitivity analysis; GI, gastro-intestinal; HR, hazard ratio; ICH, intracranial haemorrhage; IS, ischaemic stroke; MI, myocardial infarction; PSA, probabilistic sensitivity analysis; VKA, vitamin K antagonist.

[27].
was increased by 1.53 after a stroke in line with the results obtained in the XANTUS observational study [30].

For each treatment, discontinuation probabilities were divided into different time periods (initiation-3 months, 3 months-6 months, 6 months-1 year, and >1 year). For the VKA arm, treatment discontinuation and switch rates were derived from RWE studies [10, 15]. For the rivaroxaban arm, the HR of discontinuation from the RWE meta-analysis and the switch rate from a RWE French study [10, 15] were used.

Death rates based on French life tables, were applied to all modelled states. A number of health states included an additional specific event-related mortality risk, as identified from a literature review on RWE studies in France [16–19], assuming no event-related mortality followed hospital discharge.

**Utility**

Utility values were derived from recent European studies [20–22, 31] as no French data were identified. No utility decrements associated with specific treatments were considered in the base case which was explored in a scenario analysis.

**Estimation of costs**

Through the third-party payment system, patients with long-term illnesses (LTI) do not pay medical expenses. The LTI coverage was estimated to be 71.6% in these patients [32]; a 100% reimbursement rate including drug international normalized ratio (INR) testing and visit costs was assumed, while a 65% reimbursement rate was applied for non-LTI patients for drugs, 70% for practitioner visits, and 80% for hospital care.

Three relevant cost categories were identified: drug acquisition costs, administration costs (including monitoring and other costs), and clinical event-related costs.

VKA monitoring costs include direct medical costs (INR testing, pharmacy/physician consultations, and travel costs for providers to provide care and/or INR monitoring at the patient’s home) and direct non-medical costs (patient/caregiver travel costs to labs, physician offices, and pharmacy); this additional cost attributable to VKA therapy has been amounted to €81 per cycle [33].

NOACs monitoring costs related to renal and hepatic monitoring include one at-home nurse consultation and additional relevant biology tests, amounted to €16 per cycle. A GP visit was also considered as part of administration costs.

Clinical events unit costs were collected from RWE French studies [25, 26, 34]. Costs were adjusted using the consumer price index in Health sector from the National Institute of Statistics and Economic Studies. All costs have been inflated to €2017 using the consumer price.
index from the National Institute of Statistics and Economic Studies for adjustment when necessary.

**Sensitivity analyses**

A series of univariate deterministic sensitivity analyses (DSA) were run for the base case in order to determine the significant drivers of cost-effectiveness. Otherwise, the confidence interval was used as lower and upper bound of the DSA. When not available, a ±25% variation of the base value was applied for low and high values.

A stochastic component was included in the model to allow multivariate probabilistic sensitivity analyses (PSA) with 2000 iterations. All parameters with second-order uncertainty were included in the PSA. Parameters that did not carry second-order uncertainty were excluded (discount rates, time horizon, unit costs from published reference lists, and patient’s characteristics such as age and co-morbidities). A beta distribution was used for probabilities, utility values, and proportion; whereas, gamma was considered for cost. The variation used in the DSA was used as the confidence interval (CI) to estimate the distribution parameters. The PSA also allowed providing 95% CI to all model health outputs as well as incremental cost-effectiveness ratios (ICERs).

To confirm the validity of the findings, the impact of several assumptions on the results was explored through scenario analyses. A first scenario considered the inclusion of utility decrements related to treatment: an utility decrement of 0.013 was associated with VKA and an utility decrement of 0.002 was associated with rivaroxaban therapy [35]. A second scenario considered HRs from the RWE meta-analysis considering incident patients only. Indeed, bleeding usually occurs in the initial phases of anticoagulant treatment [36], so it could be less common in prevalent than incident patients. Thirdly, alternative probabilities for switches after initial treatment discontinuation were tested (0%, i.e. all patients move to no treatment after their initial treatment, and 100% i.e. all patients have another treatment after their initial treatment before discontinuing to no treatment). Finally, a scenario using the hazard ratios from the ROCKET-AF trial [11] was presented to explore the impact of using RCT data instead of RWE, when it comes to comparative effectiveness.

**Results**

**Rivaroxaban vs VKAs**

In the base-case analysis, from the NHI perspective, patients treated with rivaroxaban experienced incremental gains in both QALYs (0.12, 95% CI: [0.056; 0.178]) and LYs (0.16, 95% CI: [0.120; 0.189]) compared with VKAs. Treatment with rivaroxaban was associated with fewer MI (0.141, 95% CI: [0.139; 0.144]) for rivaroxaban vs 0.148, 95% CI: [0.147; 0.149] for VKA), and a lower rate of IS (0.389, 95% CI: [0.375; 0.405] for rivaroxaban vs 0.414, 95% CI: [0.399; 0.430] for VKA), but was associated with a higher bleeding rate (0.112, 95% CI: [0.107; 0.117] for rivaroxaban vs 0.092, 95% CI: [0.091; 0.093] for VKA). Over a lifetime horizon, costs were higher for rivaroxaban compared with VKA (€15,896, 95% CI: [14,184; 17,821] vs €15,182, 95% CI: [13,415; 17,152]), with incremental costs reaching €714, 95% CI: [271; 1,200]. This is largely due to the higher drug acquisition costs (+€1,604); however, savings were associated with the reduced rates of events (-€745) and drug administration costs (-€146). From the NHI perspective, the base-case analysis resulted in an incremental cost/QALY of €6,006, 95% CI: [2,212; 14,616] and an incremental cost/LY of €4,586, 95% CI: [1,717; 8,286] as summarized in Table 3.
Sensitivity analysis

Univariate sensitivity analyses were performed on all variables (Fig 2). The Tornado graph showed that the results were robust to plausible changes in the inputs parameters with a majority of parameters having a minimal impact on the results. The main drivers identified were the probability of major IS when not treated, the probability of MI when not treated, and the probability of ICH when treated with rivaroxaban.

Uncertainty around the cost-effectiveness results was demonstrated by plotting simulations from the PSA on a cost-effectiveness plane (Fig 3). All the probabilistic simulations suggest a QALY gain with rivaroxaban associated with an increase in cost for rivaroxaban (upper-right-hand quadrant) in 99.7% of the cases. The threshold corresponding to an 80% probability of rivaroxaban being cost-effective was estimated to €8,600 (Fig 4).

Scenario analyses were run to further test the robustness of the results. First, applying a utility decrement associated with rivaroxaban and VKA therapy reduced the incremental ratio to €5,495 per QALY gained. Second, considering treatment incident studies only in the meta-analysis reduced the incremental ratio to €5,471 per QALY gained. Thirdly, assuming no patient switch after discontinuation of initial treatment yielded to an incremental ratio of €5,507 per QALY gained while the opposite scenario assuming all patients switch, yielded to an incremental ratio of €6,228 per QALY gained. Finally, assuming all hazard ratios were taken from ROCKET-AF instead of RWE meta-analysis, increased the ICER up to €10,247.

Discussion

Although there is no official willingness-to-pay threshold in France, the above-mentioned results suggest that in the French healthcare setting, rivaroxaban could be considered as a cost-effective alternative to VKA for the prevention of stroke in AF patients, as a result of the clinical benefit shown in real-world setting. The model demonstrated that the benefits in terms of life expectancy and QALY gain were maintained over a lifetime horizon of 30 years, confirming the advantages of the strategy with rivaroxaban over VKA. Sensitivity analyses showed that uncertainty and variability in model parameters had a limited impact on results with all ICERs remaining below €11,000/QALY, suggesting a robustness of the conclusion.
To our knowledge, this analysis is the first model-based cost-effectiveness evaluation of a NOAC considering multiple RWE sources to document effectiveness (VKA rates and comparative effectiveness). A previous systematic literature review identified 18 cost-effectiveness models comparing rivaroxaban and other NOACs with VKAs for stroke prevention in patients with AF; all models derived safety and efficacy data from RCTs [37]. While the heterogeneous nature of clinical trials and modelling methods made it challenging to identify the most cost-effective agent amongst the NOACs, this review concluded that NOACs were frequently cost-effective compared to VKAs [37]. In France, two previous studies identified NOACs as cost-effective with incremental cost-effectiveness ratios below €20,000 per QALY gained compared to VKA [38] [25]. In the latter, uncertainty around RCT data used for NOACs was specifically highlighted, suggesting the need to validate the results in a French real-life context. Other published models considered RWE to document effectiveness [39–42], but none considered a meta-analysis with RWE only.

This model demonstrated a major improvement compared to the already published model. The model was also able to capture the different treatment regimens with the time on initial treatment considered through time-dependent rates, resulting in a complete discontinuation or a switch to another treatment. Additionally, RWE was considered as a key source for all model inputs, to fully reflect patients’ characteristics and disease progression seen in routine practice settings. This included population characteristics, clinical event rates, treatment effect,
discontinuation, switch rates, utility, resource use, and unit costs for all events. This was considered to be the definition of a RWE cost-effectiveness model.

The use of RWE is associated to many challenges, such as dealing with the selection bias, missing data, lack of accuracy related to drug exposure and outcomes, errors during the record-keeping process [43], and also to potential benefits. For example, it would enable a shift from surrogate outcomes to clinical and long-term outcomes and constitute an important source of information in the specific case of rare harms. It is expected that methodologies used to analyse and synthesize RWE will continue to evolve. However, little guidance is available on the relative merits of using RWE in the modelling context [43–45].

The approach presented here is not without limitations. First, the model provides a simplification of what is expected in reality. Long-term outcomes believed to reflect the consequences of AF based on a number of assumptions to capture natural disease progression. Second, in the absence of France-specific utilities, this analysis considered values based on European data, assuming a reasonable similarity with French population. Of note, the deterministic sensitivity analysis did not report any significant impact of changes in utility values on the model’s conclusions. Third, the persistence rate from the VKA arm was taken from an US study [14] as no relevant French data were identified. However, the proportion of switch among the patients who discontinued their initial treatment was taken from a French study focussing on primary care [15]. Finally, multiple health states exist in the model with the possibility for patients to transition between all of them. This flexibility has a limitation as it allows patients to recover
from major events by experiencing minor ones. As an example, a patient in post-major stroke
could experience a minor stroke, and be associated to higher utility and lower costs. As this
underestimates the burden of patients with VKA, it also underestimates the potential benefit
associated with rivaroxaban.

**Conclusion**

This RWE cost-effectiveness model in the context of stroke prevention in patients with AF
demonstrated that rivaroxaban is likely to be cost-effective vs VKA in France in a real-world
setting.

**Author Contributions**

**Conceptualization:** Kevin Bowrin.

**Methodology:** Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie
Millier, Emilie Clay, Pierre Levy.

**Project administration:** Kevin Bowrin, Aurélie Millier.

**Supervision:** Kevin Bowrin, Mondher Toumi.

**Writing – original draft:** Kevin Bowrin, Aurélie Millier, Emilie Clay.
Writing – review & editing: Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Mondher Toumi, Pierre Levy.

References

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):2071–104. Epub 2014/04/01. https://doi.org/10.1161/CIR.0000000000000430 PMID: 24682348.

2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5):e1–e88. Epub 2016/09/25. https://doi.org/10.1093/ejcts/ezw313 PMID: 27663299.

3. Kakkar A, Mueller I, Bassand J, Fitzmaurice D, Goldhaber S, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the International, observational, prospective GARFIELD registry. PLoS One. 2013; 8(5):e63479. https://doi.org/10.1371/journal.pone.0063479 PMID: 23704912.

4. Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, et al. AHRQ Comparative Effectiveness Reviews. Stroke Prevention in Atrial Fibrillation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.

5. Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol. 2014; 37(1):32–47. Epub 2013/11/21. https://doi.org/10.1002/clc.22204 PMID: 24254991.

6. Verpillat P, Dorey J, Guilhaume-Goulant C, Dabbous F, Aballea S. Ischemic stroke management in West Scotland: a chart review. J Mark Access Health Policy. 2015; 3. Epub 2015/01/01. https://doi.org/10.3402/jmahp.v3.26339 PMID: 27123179; PubMed Central PMCID: PMC4802692.

7. Stroke Alliance For Europe (SAFE). Burden of stroke report launched in EU parliament. In: London KsC, editor. 2017.

8. Blommestein HM, Franken MG, Uyl-de Groot CA. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry. Pharmacoeconomics. 2015; 33(6):551–60. https://doi.org/10.1007/s40273-015-0260-4 PMID: 25644460; PubMed Central PMCID: PMC4445765.

9. Annemans L AM, Kubin M. Real-life data: a growing need. ISPOR Connections. 2007; 13(5):8–13.

10. Coleman CI, Briere JB, Fauchier L, Levy P, Bowrin K, Toumi M, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 2019; 7(1):1574541. https://doi.org/10.1080/20016689.2019.1574541 PMID: 30774476; PubMed Central PMCID: PMC6366429.

11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–91. https://doi.org/10.1056/NEJMoa1009638 PMID: 21830957.

12. Bayer Plc. Single technology appraisal (STA) of rivaroxaban (Xarelto®). National Institute for Health and Clinical Excellence; 2011.

13. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11):1019–26. https://doi.org/10.1056/NEJMoa0109639 PMID: 12968068.

14. Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS One. 2016; 11(6):e0157769. https://doi.org/10.1371/journal.pone.0157769 PMID: 27327275; PubMed Central PMCID: PMC4915663.

15. Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefevre C, Maguire A, et al. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Arch Cardiovasc Dis. 2018; 111(5):370–9. https://doi.org/10.1016/j.acvd.2017.10.003 PMID: 29398546.

16. Fauchier L, Samson A, Chaize G, Gaudin AF, Vainchtock A, Bailly C, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart. 2015; 2(1):e000290. https://doi.org/10.1136/openhrt-2015-000290 PMID: 26688739; PubMed Central PMCID: PMC4680587.
17. Lip G, Pan X, Kambale S, Kabwabata H, Mardekan J, Masseria C, et al. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin. Eur Heart J 2015;Anticoagulation and atrial fibrillation III(P6217):1085.

18. Blin P, Philippe F, Bouee S, Laurendeau C, Torreton E, Gourmelin J, et al. Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. Int J Cardiol. 2016; 219:387–93. https://doi.org/10.1016/j.ijcard.2016.06.102 Epub 2016 Jun 23;:387–93. PMID: 27372604

19. Cotte FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand-Zaleski I. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis. 2014; 23(2):e73–83. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.08.022 PMID: 24119623

20. Kongnakorn T, Lanitis T, Annermans L, Thijis V, Goethals M, Marbaix S, et al. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost-effectiveness of new oral anticoagulants and warfarin. Clin Drug Invest. 2015; 35(2):109–19. https://doi.org/10.1007/s40261-014-0253-7 PMID: 25511639

21. Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM, et al. Quality of life following acute hospitalisation for myocardial infarction in France: An insurance claims database analysis. Int J Cardiol. 2016; 219:387–93. https://doi.org/10.1016/j.ijcard.2016.06.102 Epub 2016 Jun 23;:387–93. PMID: 27372604

22. Pockett RD, McEwan P, Beckham C, Shuter S, Martin S, Yousef Z, et al. Health utility in patients following cardiovascular events. Value Health. 2014; 17(7):A328.

23. CNAMTS. Fiche—PREVISCAN 20 MG (FLUINDIONE) 1 Boîte de 30, comprimés quadriseptés. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/fiche/index_fic_medisoc.php?p_code_cip=3409334841328&site=AMELI.

24. CNAMTS. Fiche—XARELTO 15 MG + 20 MG (RIVAROXABAN) KIT D'INITIATION: 49 COMPRIMÉS (42X15 MG + 7X20 MG), COMPRIMÉS PELLIÇULES. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/fiche/index_fic_medisoc.php?p_code_cip=3409330788538&site=AMELI.

25. Lanitis T, Cotte FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014; 17(6):587–98. https://doi.org/10.1080/13696998.2014.923891 PMID: 24831811.

26. Cotte FE, Chaize G, Gaudin AF, Samson A, Vainchtock A, Fauchier L. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europec. 2016; 18(4):501–7. https://doi.org/10.1093/europace/euv385 PMID: 26719553; PubMed Central PMCID: PMC4865060.

27. Haute Autorité de santé (HAS). Choices in Methods for Economic Evaluation. 2012.

28. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012; 5(6):941–8. CIRCEP.112.972889 [pii]; https://doi.org/10.1161/CIRCEP.112.972889 PMID: 22923275

29. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death or individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290(8):1049–56. https://doi.org/10.1001/jama.290.8.1049 PMID: 12941677

30. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37(14):1145–53. https://doi.org/10.1093/eurheartj/ehw466 PMID: 26330425; PubMed Central PMCID: PMC4823634.

31. Dewilde S, Thijis V, Annermans L, Peeters A, Belgian Stroke Council NP. Quality of life decrements after stroke. Value Health. 2014; 17(7):A331. https://doi.org/10.1016/j.jval.2014.08.622 PMID: 27200574.

32. Cohen A DJ, Durand-Zaleski I, Bouée S, Le Heuzey JY; EPHA Investigators. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 2010; 103(6–7):376–87. https://doi.org/10.1016/j.acvd.2010.06.001 Epub 2010 Jul 22. PMID: 20800801

33. Dallongeville J, Ansolabehere X, Karusisi N, Maurel F, Van Ganse E, Le Heuzey JY. Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013. J Med Econ. 2017; 20(9):974–81. https://doi.org/10.1080/13696998.2017.1352508 PMID: 28682153.

34. Sherwood A, Maurel F, Colin X. Appraising the cost of physician visits and technical procedures In France in the age of open data. Value Health. 2015; 18(7):A531–A2. https://doi.org/10.1016/j.jval.2015.09.1655

35. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996; 156(16):1829–36. PMID: 8790077.
36. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37 (38):2882–9. https://doi.org/10.1093/eurheartj/ehw233 PMID: 27357359; PubMed Central PMCID: PMC5070447.

37. Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013; 8(4):e62183. Epub 2013/04/30. https://doi.org/10.1371/journal.pone.0062183 PMID: 23626785; PubMed Central PMCID: PMC3633898.

38. Chevalier J, Delaitre O, Hammes F, de Pouvourville G. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Arch Cardiovasc Dis. 2014; 107(6–7):381–90. https://doi.org/10.1016/j.acvd.2014.04.009 PMID: 24973113.

39. de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. J Med Econ. 2019; 22(4):306–18. https://doi.org/10.1080/13696998.2018.1563404 PMID: 30614320.

40. Bennaghmouch N, de Veer A, Mahmoodi BK, Jofre-Bonet M, Lip GYH, Bode K, et al. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antplatelet therapy: a modelling analysis using the healthcare system in the Netherlands. Eur Heart J Qual Care Clin Outcomes. 2019; 5(2):127–35. https://doi.org/10.1093/ehjqcco/qcy030 PMID: 30016398.

41. Peng S, Deger KA, Ustyugova A, Gandhi P, Qiao N, Wang C, et al. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Curr Med Res Opin. 2018; 34(1):55–63. https://doi.org/10.1080/03007995.2017.1375470 PMID: 28862479.

42. Zhao YJ, Lin L, Zhou HJ, Tan KT, Chew AP, Foo CG, et al. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol. 2016; 220:794–801. https://doi.org/10.1016/j.ijcard.2016.06.087 PMID: 27400183.

43. Bowrin K, Briere JB, Levy P, Millier A, Clay E, Tourmi M. Cost-effectiveness analyses using real-world data: an overview of the literature. J Med Econ. 2019; 1–9. https://doi.org/10.1080/13696998.2019.1588737 PMID: 30816067.

44. Briere JB, Bowrin K, Taieb V, Millier A, Tourmi M, Coleman C. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Curr Med Res Opin. 2018; 1–6. https://doi.org/10.1080/03007995.2018.1524751 PMID: 3021738.

45. Levy P, Briere JB, Bowrin K, Millier A, editors. Challenges in the use of real-world evidence for pharmacoeconomic modelling. International Society for Pharmacoeconomics and Outcomes Research; 2018 10–14 November 2018; Barcelona, Spain.